Discovery of a series of imidazo[4,5-b ]pyridines with dual activity at angiotensin II Type 1 receptor and peroxisome proliferator-activated receptor-γ

Journal of Medicinal Chemistry

Volumn 54, Issue 12, 2011, Pages 4219-4233

  Casimiro Garcia, Agustin ^a   Filzen, Gary F ^a   Flynn, Declan ^a   Bigge, Christopher F ^a   Chen, Jing ^a   Davis, Jo Ann ^a   Dudley, Danette A ^a   Edmunds, Jeremy J ^a   Esmaeil, Nadia ^a   Geyer, Andrew ^a   Heemstra, Ronald J ^a   Jalaie, Mehran ^a   Ohren, Jeffrey F ^a   Ostroski, Robert ^a   Ellis, Teresa ^a   Schaum, Robert P ^a   Stoner, Chad ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [5 [2 (1H TETRAZOL 5 YL)PHENYL] 2,3 DIHYDRO 1H INDEN 1 YL) 2 ETHYL 5 ISOBUTYL 7 METHYL 3H IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CELL NUCLEUS RECEPTOR; GLUCOSE; IMIDAZO[4,5 B]PYRIDINE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TELMISARTAN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYPERTENSION; IC 50; INSULIN RESISTANCE; LIGAND BINDING; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CRYSTALLOGRAPHY, X-RAY; DRUG PARTIAL AGONISM; HUMANS; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN RESISTANCE; MALE; MODELS, MOLECULAR; PPAR GAMMA; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, INBRED SHR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTIONAL ACTIVATION; TRIGLYCERIDES;

EID: 79959444835     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200409s     Document Type: Article

References (51)

1. Alberti, K. G. M. M.; Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z.; Cleeman, J. I.; Donato, K. A.; Fruchart, J.-C.; James, W. P. T.; Loria, C. M.; Smith, S. C., Jr. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity Circulation 2009, 120, 1640-1645
2. Cutler, J. A.; Davis, B. R. Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension Circulation 2008, 117, 2691-2704
3. Messerli, F. H.; Beevers, D. G.; Franklin, S. S.; Pickering, T. G. β-Blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension Am. J. Hypertens. 2003, 16, 870-873 (Pubitemid 37204686)
4. Bertrand, M. E. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials Curr. Med. Res. Opin. 2004, 20, 1559-1569 (Pubitemid 39457544)
5. Guazzi, M. D.; Polese, A.; Fiorentini, C.; Bartorelli, A.; Moruzzi, P. Treatment of hypertension with calcium antagonists Hypertension 1983, 5, II85-90
6. Heran, B. S.; Wong, M. M.; Heran, I. K.; Wright, J. M. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension Cochrane Database Syst. Rev. 2008, 4, CD003822
7. Moutzouri, E.; Florentin, M.; Elisaf, M. S.; Mikhailidis, D. P.; Liberopoulos, E. N. Aliskiren, a direct renin inhibitor, in clinical practice: a new approach in the treatment of hypertension Curr. Vasc. Pharmacol. 2010, 8, 344-362
8. Lloyd-Jones, D.; Adams, R.; Carnethon, M.; De Simone, G.; Ferguson, T. B.; Flegal, K.; Ford, E.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, M.; Howard, V. The american heart association statistics committee and stroke statistics subcommittee Circulation 2009, 119, e21-e181
9. Saydah, S. H.; Eberhardt, M. S.; Loria, C. M.; Brancati, F. L. Subclinical stales of glucose intolerance and risk of death in the US Diabetes Care 2001, 24, 447-453 (Pubitemid 32198411)
10. Khaw, K. T.; Wareham, N.; Bingham, S.; Luben, R.; Welch, A.; Day, N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk Ann. Intern. Med. 2004, 141, 413-420
11. Klein, S.; Sheard, N. F.; Pi-Sunyer, X.; Daly, A.; Wylie-Rosett, J.; Kulkarni, K.; Clark, N. G. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition Diabetes Care 2004, 27, 2067-2073 (Pubitemid 38989258)
12. Chia, C. W.; Egan, J. M. Role and development of GLP-1 receptor agonists in the management of diabetes Diabetes Metab. Syndr. Obes. 2009, 2, 37-49
13. Drab, S. R. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects Pharmacotherapy 2010, 30, 609-624
14. Choi, J. H.; Banks, A. S.; Estall, J. L.; Kajimura, S.; Bostrom, P.; Laznik, D.; Ruas, J. L.; Chalmers, M. J.; Kamenecka, T. M.; Bluher, M.; Griffin, P. R.; Spiegelman, B. M. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5 Nature 2010, 466, 451
15. de Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors Pharmacol. Rev. 2000, 52, 415-472
16. Benson, S. C.; Pershadsingh, H. A.; Ho, C. I.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi, N.; Wang, J.; Avery, M. A.; Kurtz, T. W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity Hypertension 2004, 43, 993-1002 (Pubitemid 38579904)
17. Vitale, C.; Mercuro, G.; Castiglioni, C.; Cornoldi, A.; Tulli, A.; Fini, M.; Volterrani, M.; Rosano, G. M. C. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome Cardiovasc. Diabetol. 2005, 4, 6-13
18. Goebel, M.; Clemenz, M.; Staels, B.; Unger, T.; Kintscher, U.; Gust, R. Characterization of new PPARγ agonists: analysis of telmisartans structural components ChemMedChem 2009, 4, 445-456
19. Goebel, M.; Staels, B.; Unger, T.; Kintscher, U.; Gust, R. Characterization of New PPARγ Agonists: Benzimidazole Derivatives-the Importance of Position 2 ChemMedChem 2009, 4, 1136-1142
20. Goebel, M.; Wolber, G.; Markt, P.; Staels, B.; Unger, T.; Kintscher, U.; Gust, R. Characterization of new PPARγ agonists: Benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode Bioorg. Med. Chem. 2010, 18, 5885-5895
21. Chittiboyina, A. G.; Mizuno, C. S.; Desai, P. V.; Patny, A.; Kurtz, T. W.; Pershadsingh, H. A.; Speth, R. C.; Karamyan, V.; Avery, M. A. Design, synthesis, and docking studies of novel telmisartan-glitazone hybrid analogs for the treatment of metabolic syndrome Med. Chem. Res. 2009, 18, 589-610
22. Mizuno, C. S.; Chittiboyina, A. G.; Patny, A.; Kurtz, T. W.; Pershadsingh, H. A.; Speth, R. C.; Karamyan, V. T.; Avery, M. A. Design, synthesis, and docking studies of telmisartan analogs for the treatment of metabolic syndrome Med. Chem. Res. 2009, 18, 611-628
23. Mizuno, C. S.; Chittiboyina, A. G.; Shah, F. H.; Patny, A.; Kurtz, T. W.; Pershadsingh, H. A.; Speth, R. C.; Karamyan, V. T.; Carvalho, P. B.; Avery, M. A. Design, Synthesis, and Docking Studies of Novel Benzimidazoles for the Treatment of Metabolic Syndrome J. Med. Chem. 2010, 53, 1076-1085
24. A preliminary report of this work was presented recently: Casimiro-Garcia, A.; Bigge, C. F.; Chen, J.; Davis, J. A.; Dudley, D. A.; Edmunds, J. J.; Esmaeil, N.; Filzen, G.; Flynn, D.; Geyer, A.; Heemstra, R. J.; Jalaie, M.; Ohren, J. F.; Padalino, T.; Pulaski, J.; Schaum, R. P.; Stoner, C. L. Discovery of a series of imidazo[4,5- b ]pyridines with dual action as angiotensin II type 1 receptor (AT1) antagonists and partial PPARgamma agonists. 239th American Chemical Society Meeting, San Francisco, CA, United States. March 2010. MEDI-200.
25. Carpino, P. A.; Wester, R. T.; Da Silva Jardine, P. A. Angiotensin II receptor antagonists. US5338740. 1994.
26. Carpino, P. A.; Sneddon, S. F.; Da Silva Jardine, P.; Magnus-Ayritey, G. T.; Rauch, A. L.; Burkard, M. R. A conformationally restrained series of AT1-selective angiotensin II antagonists Bioorg. Med. Chem. Lett. 1994, 4, 93-98 (Pubitemid 24128692)
27. Senanayake, C. H.; Fredenburgh, L. E.; Reamer, R. A.; Liu, J.; Larsen, R. D.; Verhoeven, T. R.; Reider, P. J. Magnesium-assisted imidazole formation from unreactive ureas Tetrahedron Lett. 1994, 35, 5775-5778 (Pubitemid 24261677)
28. Corey, E. J.; Bakshi, R. K.; Shibata, S. Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implications J. Am. Chem. Soc. 1987, 109, 5551-5553
29. Corey, E. J.; Helal, C. J. Reduction of carbonyl compounds with chiral oxazaborolidine catalysts: A new paradigm for enantioselective catalysis and a powerful new synthetic method Angew. Chem., Int. Ed. 1998, 37, 1986-2012 (Pubitemid 28397934)
30. Lo, Y. S.; Rossano, L. T. Preparation of tetrazolylphenylboronic acid intermediates for the synthesis of angiotensin II receptor antagonists. US5130439. 1992.
31. Mantlo, N. B.; Chakravarty, P. K.; Ondeyka, D. L.; Siegl, P. K. S.; Chang, R. S.; Lotti, V. J.; Faust, K. A.; Schorn, T. W.; Chen, T. B.; Schorn, T. W.; Sweet, C. S.; Emmert, S. E.; A., P. A.; J., G. W. Potent, orally active imidazo[4,5- b ]pyridine-based angiotensin II receptor antagonists J. Med. Chem. 1991, 34, 2919-2922
32. Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D. M.; Rizzi, J. P. Novel thiazolidine-2,4-diones as potent euglycemic agents J. Med. Chem. 1992, 35, 1853-1864
33. Casimiro-Garcia, A.; Bigge, C. F.; Davis, J. A.; Padalino, T.; Pulaski, J.; Ohren, J. F.; McConnell, P.; Kane, C. D.; Royer, L. J.; Stevens, K. A.; Auerbach, B. J.; Collard, W. T.; McGregor, C.; Fakhoury, S. A.; Schaum, R. P.; Zhou, H. Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARα/γ dual agonists, and X-ray crystallographic studies Bioorg. Med. Chem. 2008, 16, 4883-4907 (Pubitemid 351625893)
34. Casimiro-Garcia, A.; Bigge, C. F.; Davis, J. A.; Padalino, T.; Pulaski, J.; Ohren, J. F.; McConnell, P.; Kane, C. D.; Royer, L. J.; Stevens, K. A.; Auerbach, B.; Collard, W.; McGregor, C.; Song, K. Synthesis and evaluation of novel α-heteroaryl-phenylpropanoic acid derivatives as PPARα/γ dual agonists Bioorg. Med. Chem. 2009, 17, 7113-7125
35. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13919-13924 (Pubitemid 33115999)
36. Nettles, K. W. Insights into PPARγ from structures with endogenous and covalently bound ligands Nat. Struct. Mol. Biol. 2008, 15, 893-895
37. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-γ Nature 1998, 395, 137-143 (Pubitemid 28425645)
38. Patani, G. A.; LaVoie, E. J. Bioisosterism: a rational approach in drug design Chem. Rev. 1996, 96, 3147-3176 (Pubitemid 126641132)
39. Middlemiss, D.; Watson, S. P. A medicinal chemistry case study. An account of an angiotensin II antagonist drug discovery programme Tetrahedron 1994, 50, 13049-13080 (Pubitemid 124019691)
40. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy J. Med. Chem. 1996, 39, 625-656 (Pubitemid 26069685)
41. Morsing, P.; Adler, G.; Brandt-Eliasson, U.; Karp, L.; Ohlson, K.; Renberg, L.; Sjoquist, P.-O.; Abrahamsson, T. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin Hypertension 1999, 33, 1406-1413 (Pubitemid 29282662)
42. Gradman, A. H. AT1-receptor blockers: differences that matter J. Hum. Hypertens. 2002, 16, S9-S16
43. Maillard, M. P.; Perregaux, C.; Centeno, C.; Stangier, J.; Wienen, W.; Brunner, H.-R.; Burnier, M. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist J. Pharmacol. Exp. Ther. 2002, 302, 1089-1095 (Pubitemid 34920230)
44. Sharpe, M.; Jarvis, B.; Goa, K. L. Telmisartan: a review of its use in hypertension Drugs 2001, 61, 1501-1529 (Pubitemid 32783749)
45. Stucky, G.; Imwinkelried, R. Preparation of imidazopyridines. EP645389. 1995.
46. Otwinowski, Z.; Minor, W. Processing of x-ray diffraction data collected in oscillation mode. In Macromolecular Crystallography, Part A., Carter, C. W., Jr.; Sweet, R. M., Ed. Academic Press: New York, 1997; Vol. 276, pp 307-326. (Pubitemid 27085611)
47. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 (Pubitemid 30047768)
48. Bailey, S. The CCP4 suite: programs for protein crystallography Acta Crystallogr. 1994, D50, 760-763
49. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. 1997, D53, 240-255 (Pubitemid 27235885)
50. Roversi, P.; Blanc, E.; Vonrhein, C.; Evans, G.; Bricogne, G. Modelling prior distributions of atoms for macromolecular refinement and completion Acta Crystallogr. 2000, D56, 1316-1323
51. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr. 2010, D66, 486-501